Sinopharm Group Co. Ltd. (HKG:1099)
Hong Kong · Delayed Price · Currency is HKD 16.78
-0.30 (-1.76%)
Jun 9, 2026, 9:55 AM HKT
Sinopharm Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 7,112 | 7,155 | 7,050 | 9,054 | 8,526 | 7,759 |
Depreciation & Amortization | 4,066 | 4,066 | 4,529 | 4,244 | 4,002 | 3,783 |
Other Amortization | 237.95 | 237.95 | 201.88 | 166.75 | 147.53 | 126.74 |
Loss (Gain) From Sale of Assets | -20.53 | -20.53 | -79.91 | -492.31 | -3.11 | -65.87 |
Asset Writedown & Restructuring Costs | 591.54 | 591.54 | 1,102 | 80.36 | 95.7 | 648.22 |
Loss (Gain) From Sale of Investments | 2,248 | 2,248 | 2,568 | 2,637 | 5,159 | 930.13 |
Loss (Gain) on Equity Investments | -1,233 | -1,233 | -1,199 | -1,107 | -1,067 | -1,070 |
Provision & Write-off of Bad Debts | 845.09 | 845.09 | 1,323 | 614.54 | 431.88 | 445.77 |
Other Operating Activities | 5,150 | 2,999 | 2,523 | 5,841 | 5,746 | 8,841 |
Change in Accounts Receivable | -7,775 | -7,775 | -17,369 | -14,850 | 710.12 | -26,717 |
Change in Inventory | -1,106 | -1,106 | -2,040 | 455.56 | -9,504 | -4,345 |
Change in Accounts Payable | 7,480 | 7,480 | 6,218 | 10,784 | 8,315 | 19,805 |
Change in Unearned Revenue | -844.7 | -844.7 | 553.42 | -3,961 | 4,314 | -1,265 |
Change in Other Net Operating Assets | -506.43 | -506.43 | 6,166 | 3,706 | -5,909 | 421.26 |
Operating Cash Flow | 16,246 | 14,138 | 11,546 | 17,173 | 20,964 | 9,308 |
Operating Cash Flow Growth | -34.37% | 22.45% | -32.77% | -18.08% | 125.22% | -16.55% |
Capital Expenditures | -1,529 | -1,496 | -1,471 | -1,960 | -2,127 | -2,074 |
Sale of Property, Plant & Equipment | 20.2 | 19.23 | 65.74 | 456.13 | 172.34 | 134.01 |
Cash Acquisitions | - | - | -209.61 | -108.24 | -449.15 | -497.22 |
Divestitures | 81.94 | 66.91 | 24.99 | 26.44 | 81.18 | 6.12 |
Sale (Purchase) of Intangibles | -107.96 | -107.96 | -266.95 | -324.01 | -188.75 | -153.06 |
Sale (Purchase) of Real Estate | 0.01 | 0.01 | 0.18 | 28.82 | 0.63 | 1.14 |
Investment in Securities | 47.42 | 83.2 | 68.56 | 102.59 | -51.17 | -8.15 |
Other Investing Activities | -447.67 | 470.47 | -1,962 | 833.32 | -1,028 | 1,324 |
Investing Cash Flow | -1,935 | -963.89 | -3,751 | -944.54 | -3,590 | -1,267 |
Long-Term Debt Issued | - | 107,974 | 106,926 | 106,438 | 106,451 | 99,922 |
Total Debt Issued | 105,944 | 107,974 | 106,926 | 106,438 | 106,451 | 99,922 |
Long-Term Debt Repaid | - | -120,871 | -116,861 | -106,052 | -103,530 | -106,464 |
Total Debt Repaid | -124,473 | -120,871 | -116,861 | -106,052 | -103,530 | -106,464 |
Net Debt Issued (Repaid) | -18,529 | -12,898 | -9,935 | 385.68 | 2,921 | -6,543 |
Common Dividends Paid | -2,006 | -2,122 | -2,715 | -2,559 | -2,340 | -2,153 |
Other Financing Activities | -3,210 | -3,667 | -4,635 | -5,471 | -6,274 | -5,997 |
Financing Cash Flow | -23,745 | -18,687 | -17,285 | -7,644 | -5,693 | -14,693 |
Foreign Exchange Rate Adjustments | -11.58 | -4.9 | -5.24 | 2.39 | 11.51 | 3.05 |
Net Cash Flow | -9,446 | -5,517 | -9,495 | 8,587 | 11,692 | -6,649 |
Free Cash Flow | 14,717 | 12,642 | 10,075 | 15,213 | 18,837 | 7,234 |
Free Cash Flow Growth | -37.20% | 25.49% | -33.78% | -19.23% | 160.38% | -21.85% |
Free Cash Flow Margin | 2.56% | 2.20% | 1.72% | 2.55% | 3.41% | 1.39% |
Free Cash Flow Per Share | 4.70 | 4.05 | 3.23 | 4.88 | 6.04 | 2.32 |
Cash Interest Paid | 2,474 | 2,474 | 3,322 | 3,199 | 4,778 | 4,575 |
Cash Income Tax Paid | 4,937 | 4,741 | 4,456 | 4,575 | 4,399 | 4,074 |
Levered Free Cash Flow | -2,768 | 2,775 | -6,917 | 10,158 | 15,174 | -2,358 |
Unlevered Free Cash Flow | -1,374 | 4,208 | -5,214 | 12,000 | 17,368 | -17.52 |
Change in Working Capital | -2,752 | -2,752 | -6,471 | -3,864 | -2,074 | -12,101 |